Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

David L. Grinblatt, Gail J. Roboz, Daniel A. Pollyea, Mikkael A. Sekeres, Bart L. Scott, Karen Seiter, Amer M. Zeidan, Jay L. Patel, Guillermo Garcia-Manero, Rami S. Komrokji, Michael R. Savona, Irene S. Degutis, Pavel Kiselev, Edward Yu, Willem Heydendael, Ying Qiu, Sara Vergara, Ali McBride, Harry P. Erba

Blood (2023) 142 (Supplement 1): 593.

https://doi.org/10.1182/blood-2023-189963

Published: 2023

Journal Articles

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Ben A Derman, Tadeusz Kubicki, Heidi Simmons, Aimaz Afrough, Jeffrey A. Zonder, David L. Grinblatt, Larry D. Anderson, Jr., Andrew Kin, Sunil Narula, Shayan Rayani, Sandeep Gurbuxani, Theodore Karrison, Ken Jiang, Ajay Major, Jennifer H Cooperrider, Allison P. Jacob, Andrzej J Jakubowiak

Blood (2023) 142 (Supplement 1): 1982.

https://doi.org/10.1182/blood-2023-182410

Published: 2023

Journal Articles

Streamline - Retrospective Cohort Study of FLT3- mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis

Amer M. Zeidan, Santosh Gautam, Rebekah Yu, Ziyu Lan, David L. Grinblatt, Dina ElSouda, James Spalding, Alana Block, Maelys Touya, Bhavik J. Pandya

Blood (2022) 140 (Supplement 1): 8124–8126.

https://doi.org/10.1182/blood-2022-166692

Published: 2022

Journal Articles

Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes

Mikkael A. Sekeres, Guillermo Garcia-Manero, David L. Grinblatt, Rami S. Komrokji, Michael R. Savona, Harry P. Erba, Gail J. Roboz, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Adeola Y. Makinde, Ali McBride, Bart L. Scott

Blood (2022) 140 (Supplement 1): 9818–9820.

https://doi.org/10.1182/blood-2022-158075

Published: 2022

Journal Articles

Real-World Use of FLT3 Tyrosine Kinase Inhibitors in Patients with Relapsed/Refractory FLT3 mutation-Positive Acute Myeloid Leukemia in the United States

David L. Grinblatt, Wei Han, David Nimke, Qi Feng, Loretta Sullivan, Bhavik J. Pandya

Blood (2021) 138 (Supplement 1): 5033.

https://doi.org/10.1182/blood-2021-145387

Published: 2021

Journal Articles

Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry

Rami S. Komrokji, Tracy I. George, Harry P. Erba, Bart L. Scott, David L. Grinblatt, Jaroslaw P. Maciejewski, Gail J. Roboz, Michael R. Savona, Guillermo Garcia-Manero, Irene S. DeGutis, Pavel Kiselev, Edward Yu, Adeola Y. Makinde, Mikkael A. Sekeres

Blood (2021) 138 (Supplement 1): 3686.

https://doi.org/10.1182/blood-2021-145853

Published: 2021

Journal Articles

Connect ® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study

Christopher R. Flowers, David Andorsky, John M. Burke, James R. Cerhan, David L. Grinblatt, Chris L. Pashos, Kathleen Toomey, Andrew D. Zelenetz, Kristen Sullivan, E. Dawn Flick, Pavel Kiselev, Mark Kaplan, Jung Ryun Ahn

Blood (2021) 138 (Supplement 1): 1460.

https://doi.org/10.1182/blood-2021-145135

Published: 2021

Journal Articles

Real-World Use of FLT3-TKIs in R/R FLT3-M utated AML in the United States

David L. Grinblatt, MD, Bhavik J. Pandya, PharmD, Wei Han, PhD, Loretta Sullivan, MD MPH, Qi Feng, PhD MS, Nancy Hedlund, PhD MBA, RPh

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136391

Published: 2020

Journal Articles

Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

Amer M. Zeidan, MBBS, MHS, Adrienne M. Gilligan, PhD, Santosh Gautam, PhD, David L. Grinblatt, MD, Dina Elsouda, Loretta Sullivan, MD MPH, Bhavik J. Pandya, PharmD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136366

Published: 2020

Journal Articles

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

Amer M. Zeidan, MBBS, MHS, Adrienne Gilligan, PhD, Santosh Gautam, Nan Hu, David L. Grinblatt, Bhavik J. Pandya, PharmD

Blood (2019) 134 (Supplement_1): 5082.

https://doi.org/10.1182/blood-2019-123535

Published: 2019

Journal Articles

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Tracy I. George, MD, Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami Komrokji, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, David P. Steensma, MD, E. Dawn Flick, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Arlene S. Swern, Kathryn Foucar

Blood (2019) 134 (Supplement_1): 4747.

https://doi.org/10.1182/blood-2019-122913

Published: 2019

Journal Articles

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Christopher R. Cogle, MD, Guillermo Garcia-Manero, MD, David L. Grinblatt, Rami S. Komrokji, MD, Michael R. Savona, MD, Bart L. Scott, MD, Mikkael A. Sekeres, MD MS, Chrystal U. Louis, E. Dawn Flick, Melissa Nifenecker, Pavel Kiselev, Arlene S. Swern, David P. Steensma

Blood (2018) 132 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2018-99-111145

Published: 2018

Journal Articles

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Inhye E Ahn, MD, Charles Michael Farber, MD PhD, Matthew Davids, MD, David L. Grinblatt, MD, Nicole Lamanna, MD, Anthony R. Mato, MDMSCE, Chadi Nabhan, MD MBA, FACP, Pavel Kiselev, PhD, Arlene S. Swern, PhD, E. Dawn Flick, RPh, MPH, ScD, Shriya Bhushan, PharmD, Kristen Sullivan, MBA, CCRA, Jeff Sharman, MD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 3581.

https://doi.org/10.1182/blood.V128.22.3581.3581

Published: 2016

Journal Articles

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Blood (2016) 128 (22): 3548.

https://doi.org/10.1182/blood.V128.22.3548.3548

Published: 2016

Journal Articles

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Jeff Sharman, MD, Matthew Davids, MD, Charles Michael Farber, MD PhD, David L. Grinblatt, MD, Neil E. Kay, MD, Nicole Lamanna, MD, Anthony R. Mato, MD, Chadi Nabhan, MD MBA, FACP, Kristen Sullivan, MBA, CCRA, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Christopher R. Flowers, MD

Blood (2016) 128 (22): 5941.

https://doi.org/10.1182/blood.V128.22.5941.5941

Published: 2016

Journal Articles

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Charles M. Farber, MD, Anthony Mato, MD, Chadi Nabhan, MD, Thomas J. Kipps, MD, PhD, Christopher Flowers, MD, Neil E. Kay, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Mark Kozloff, MD, Mark Weiss, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 5270.

https://doi.org/10.1182/blood.V126.23.5270.5270

Published: 2015

Journal Articles

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Anthony Mato, MD, Chadi Nabhan, MD, Christopher Flowers, MD, Neil E. Kay, MD, Thomas J. Kipps, MD, PhD, David L. Grinblatt, MD, Nicole Lamanna, MD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 4483.

https://doi.org/10.1182/blood.V126.23.4483.4483

Published: 2015

Journal Articles

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Christopher Flowers, MD, Chadi Nabhan, MD, Neil E. Kay, MD, Anthony Mato, MD, Nicole Lamanna, MD, David L. Grinblatt, MD, Thomas J. Kipps, MD, PhD, Mark Kozloff, MD, Kristen Sullivan, E. Dawn Flick, RPh, MPH, ScD, Pavel Kiselev, PhD, Shriya Bhushan, PharmD, Arlene S. Swern, PhD, Jeff P. Sharman, MD

Blood (2015) 126 (23): 3284.

https://doi.org/10.1182/blood.V126.23.3284.3284

Published: 2015

Journal Articles

Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry

Chadi Nabhan, MD FACP, Natalie Galanina, MD, Neil E. Kay, MD, Anthony R. Mato, MD, David L. Grinblatt, MD, Thomas J. Kipps, MD, Nicole Lamanna, MD, Mark Weiss, MD, Ian Flinn, Arlene S. Swern, PhD, Thomas Street, Sullivan Kristen, MBA, Christopher R. Flowers, MD

Blood (2014) 124 (21): 4672.

https://doi.org/10.1182/blood.V124.21.4672.4672

Published: 2014

Journal Articles

Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect ® CLL Registry

Jeff P. Sharman, MD, Anthony Mato, Neil E. Kay, MD, Thomas J. Kipps, MD, Nicole Lamanna, Mark Weiss, MD, Chadi Nabhan, Ian Flinn, David L. Grinblatt, Mark F. Kozloff, Charles M. Farber, Kirsten Sullivan, Thomas Street, Arlene S. Swern, PhD, Christopher R. Flowers, MD

Blood (2014) 124 (21): 3338.

https://doi.org/10.1182/blood.V124.21.3338.3338

Published: 2014

NARROW

Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study

Early Peripheral Blood Minimal Residual Disease Status By NGS in Patients with Newly Diagnosed Multiple Myeloma (MM) on a Phase 2 Trial Receiving Elotuzumab, Carfilzomib, Lenalidomide, and Dexamethasone (Elo-KRd)

Streamline - Retrospective Cohort Study of FLT3- mutated Acute Myeloid Leukemia (AML): Real-World Treatment Patterns and Clinical Outcomes after First Relapse or Refractory (R/R) Diagnosis

Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes

Real-World Use of FLT3 Tyrosine Kinase Inhibitors in Patients with Relapsed/Refractory FLT3 mutation-Positive Acute Myeloid Leukemia in the United States

Treatment Patterns and Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes in the Connect ® Myeloid Disease Registry

Connect ® Lymphoma Disease Registry: A US-Based, Prospective, Observational Cohort Study

Real-World Use of FLT3-TKIs in R/R FLT3-M utated AML in the United States

Streamline - Retrospective Cohort Study of Relapsed or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML): Real-World Treatment, Testing Patterns, and Outcomes

Streamline - Study of Relapse or Refractory (R/R) FLT3 -Mutated Acute Myeloid Leukemia (AML) Using Electronic Medical Records (EMR): First Analysis from a Multicenter, Retrospective Cohort Study

Diagnostic Testing Patterns and Concordance with World Health Organization (WHO) Criteria for Patients (Pts) with Newly Diagnosed (ND) Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Registry

Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect ® MDS/AML Disease Registry

Early Progression of Disease (< 2 Years) Is a Negative Predictor of Survival in Patients (Pts) with Chronic Lymphocytic Leukemia (CLL): An Analysis from the Connect ® CLL Registry

Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT ® Myelodysplastic Syndromes (MDS) and AML Disease Registry

Characteristics of Patients (Pts) with Chronic Lymphocytic Leukemia (CLL) Receiving Rituximab Monotherapy in the Connect ® CLL Registry

Analysis of Early Mortality of Chronic Lymphocytic Leukemia (CLL) Patients Treated in US Practices in the Connect CLL® Registry

Treatment Selection and Practice Patterns for the Management of High-Risk Chronic Lymphocytic Leukemia (CLL) in the US: An Analysis of the Impact of Risk Stratification on Treatment Selection from the Connect CLL® Registry

Reasons for Initiation of First-Line Therapy and Early Outcomes for Patients (Pts) with Rai 0/1 Chronic Lymphocytic Leukemia (CLL): An Analysis of the Connect CLL® Cohort Study

Patterns of Care of Aged Chronic Lymphocytic Leukemia Patients in the United States: Systematic Analysis of 457 Patients in the Connect CLL Registry

Demographics By Age Group (AG) and Line of Therapy (LOT) in Chronic Lymphocytic Leukemia (CLL) Patients (Pts) Treated in US Practices from the Connect ® CLL Registry

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only